Edward Loftus

Professor of Medicine

Mayo Clinic Rochester

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Edward Loftus is a Professor of Medicine at Mayo Clinic Rochester, United States. His research primarily focuses on inflammatory bowel disease, with recent articles highlighting the efficacy and safety of various biologics and therapies in treating Crohn's disease and ulcerative colitis. He has contributed to advancing knowledge in the area of corticosteroid-sparing treatments and the long-term management of patients with inflammatory bowel diseases.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (5)

Sunanda V Kane

Mayo Clinic College of Medicine and Science

UNITED STATES

View details

Taku Kobayashi

Kitasato University

JAPAN

View details

Joana Torres

Professora Auxiliar

Faculty of Medicine, University of Lisbon

PORTUGAL

View details

Manuel B Braga Neto

Assistant Professor

Cleveland Clinic

UNITED STATES

View details

David Rubin

Professor

University of Chicago

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Edward Loftus

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

The Future of Inflammatory Bowel Disease Care

Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn’s disease: 2-year results from the U-ENDURE Long-Term Extension study

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn’s Disease and Ulcerative Colitis

Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis

Differentiating clinical characteristics of perianal inflammatory bowel disease from perianal hidradenitis suppurativa

Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial

Certolizumab Pegol Treatment in Patients With Crohn’s Disease: Final Safety Data From the SECURE Registry

Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis

Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease

Adalimumab Therapeutic Drug Monitoring Improves Treatment Outcome in Patients with Psoriasis

Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT–Fatigue) in Patients with Crohn’s Disease and Ulcerative Colitis

Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays

Osteonecrosis in Inflammatory Bowel Disease: Clinical Features, Risk Factor Analysis, and Outcomes

Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program

Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn’s Disease

Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study

Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials

The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries

Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis

Collaborators (5)

Sunanda V Kane

Taku Kobayashi

Joana Torres

Manuel B Braga Neto

David Rubin

Make your next move.